# The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma

> **NCT07073833** · PHASE1 · RECRUITING · sponsor: **Imbioray (Hangzhou) Biomedicine Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** IBR900 cell injection
- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT07073833
- **Lead sponsor:** Imbioray (Hangzhou) Biomedicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-20
- **Primary completion:** 2027-07-30
- **Final completion:** 2028-07-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07073833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07073833, "The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07073833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*